Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used...
Main Authors: | Aline Baldo, Amaya Leunda, Nicolas Willemarck, Katia Pauwels |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/5/453 |
Similar Items
-
Approaches to quality control, preclinical and clinical studies of live recombinant viral vector vaccines
by: L. M. Khantimirova, et al.
Published: (2021-12-01) -
Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena
by: Vivek P. Chavda, et al.
Published: (2022-04-01) -
Recombinant Pichinde viral vector expressing tuberculosis antigens elicits strong T cell responses and protection in mice
by: Natalie M. Kirk, et al.
Published: (2023-02-01) -
Development of a Recombinant Pichinde Virus-Vectored Vaccine against Turkey Arthritis Reovirus and Its Immunological Response Characterization in Vaccinated Animals
by: Pawan Kumar, et al.
Published: (2021-02-01) -
Review of candidate vaccines for the prevention of Lassa fever
by: O. D. Popova, et al.
Published: (2021-05-01)